Exploiting receptor tyrosine kinase co-activation for cancer therapy

Aik Choon Tan, Simon Vyse, Paul H. Huang

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Studies over the past decade have shown that many cancers have evolved receptor tyrosine kinase (RTK) co-activation as a mechanism to drive tumour progression and limit the lethal effects of therapy. This review summarises the general principles of RTK co-activation and discusses approaches to exploit this phenomenon in cancer therapy and drug discovery. Computational strategies to predict kinase co-dependencies by integrating drug screening data and kinase inhibitor selectivity profiles will also be described. We offer a perspective on the implications of RTK co-activation on tumour heterogeneity and cancer evolution and conclude by surveying emerging computational and experimental approaches that will provide insights into RTK co-activation biology and deliver new developments in effective cancer therapies.

Original languageEnglish
Pages (from-to)72-84
Number of pages13
JournalDrug Discovery Today
Volume22
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Exploiting receptor tyrosine kinase co-activation for cancer therapy'. Together they form a unique fingerprint.

  • Cite this